SECURITIESAND EXCHANGE COMMISSION
TOSECTION 13 or 15(d) OF THE
SECURITIESEXCHANGE ACT OF 1934
Date ofreport (Date of earliest event reported): October 7,2019
(ExactName of Registrant as Specified in Its Charter)
(Stateor Other Jurisdiction of Incorporation)
(I.R.S.Employer Identification No.)
6 Road696, Dorado, Puerto Rico
(Addressof Principal Executive Offices)
(Registrant’sTelephone Number, Including Area Code)
(FormerName or Former Address, if Changed Since Last Report)
Checkthe appropriate box below if the Form 8-K filing is intended tosimultaneously satisfy the filing obligation of the registrantunder any of the following provisions (see General Instruction A.2.below):
☐Written communications pursuant to Rule 425 under the SecuritiesAct (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under theExchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under theExchange Act (17 CFR 240.13e-4(c))
Securitiesregistered pursuant to Section 12(b) of the Act: None
Title of each class
Name of each exchange on which registered
Indicateby check mark whether the registrant is an emerging growth companyas defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b2 of the Securities Exchange Act of 1934(17 CFR §240.12b2).
Emerging growthcompany ☐
If anemerging growth company, indicate by check mark if the registranthas elected not to use the extended transition period for complyingwith any new or revised financial accounting standards providedpursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure ofDirectors or Certain Officers; Election of Directors; Appointmentof Certain Officers; Compensatory Arrangements of CertainOfficers.
OnOctober 7, 2019, Pharma-Bio Serv, Inc. (the “Company”)amended the Employment Agreement, of Pedro J. Lasanta, ChiefFinancial Officer of the Company, dated November 5, 2007, asamended (the "Amendment"). The Amendment modifies Mr.Lasanta's annual salary from $160,000 to $175,000 as of October 7,2019.
Acopy of the Amendment is attached as Exhibit 10.1 to this reportand is incorporated herein by this reference.
Item 9.01. Financial Statementsand Exhibits.
EmploymentAgreement Amendment, dated October 7, 2019, by and between theCompany and Pedro J. Lasanta.
Pursuantto the requirements of the Securities Exchange Act of 1934, theregistrant has duly caused this report to be signed on its behalfby the undersigned hereunto duly authorized.
|Date:October 11, 2019|
Chief ExecutiveOfficer and President Europe Operations